The convergence of AI and drug delivery is opening new frontiers in precision medicine. AI-powered predictive modeling is ...

Mycobacterium abscessus is a fast-growing, pathogenic mycobacteria that can cause lung infections, and people who have ...

UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic hypoparathyroidism. The Calypso trial (NCT05778071) of eneboparatide, an ...

But if we can’t ban pharmaceutical ads, we can at least rein them in. Policymakers can play an integral role in addressing the manipulative advertising practices rampant in the industry, while still ...

Small amounts of a common antibiotic and anti-inflammatory drug can curb symptoms where a misplaced immune reaction (e.g., ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

Many trials exclude certain groups, and do so deliberately—children, for example, or people with physical or learning ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update First Patient Dosed in Phase 2b Trial of Halneuron® On March 18, 2025 ...

The VER-01 therapy – a cannabis extract that includes the full range of cannabinoid compounds including low levels of THC – was effective as a treatment for chronic lower back pain in a pair of ...

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...

On March 12, 2025, China's Center for Drug Evaluation (CDE) approved Tasly's Investigational New Drug (IND) application for NR-20201, an allogeneic adipose-derived mesenchymal stromal cell, sparking ...